Clinical Trial Update: Cetuximab, 5-FU and Radiation as Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update on neoadjuvant cetuximab, 5-FU, and radiation for locally advanced rectal cancer; study terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rectal Cancer

Drugs mentioned

• 5-Fluorouracil (5-FU)
• Cetuximab (cetuximab)
• radiation

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Rectal Cancer | Phase 2 | Status: TERMINATED | Results posted: 2018-11-14